Advertisement
UK markets closed

  • NIKKEI 225

    38,202.37
    -632.73 (-1.63%)
     

  • HANG SENG

    18,313.86
    -165.51 (-0.90%)
     

  • CRUDE OIL

    79.24
    +0.25 (+0.32%)
     

  • GOLD FUTURES

    2,315.50
    -6.80 (-0.29%)
     

  • DOW

    39,056.39
    +172.13 (+0.44%)
     

  • Bitcoin GBP

    49,187.04
    -1,218.56 (-2.42%)
     

  • CMC Crypto 200

    1,307.04
    +12.37 (+0.96%)
     

  • NASDAQ Composite

    16,302.76
    -29.80 (-0.18%)
     

  • UK FTSE All Share

    4,544.24
    +21.25 (+0.47%)
     
Money:

How to make a tax-free income

Tips for making money that won't be taxed

Here's Why Exelixis (EXEL) is a Strong Value Stock

Zacks Equity Research
·2-min read

Taking full advantage of the stock market and investing with confidence are common goals for new and old investors alike.

Many investors also have a go-to methodology that helps guide their buy and sell decisions. One way to find winning stocks based on your preferred way of investing is to use the Zacks Style Scores, which are indicators that rate stocks based on three widely-followed investing types: value, growth, and momentum.

Why Investors Should Pay Attention to This Value Stock

Value investors love finding good stocks at good prices, especially before the broader market catches on to a stock's true value. Utilizing ratios like P/E, PEG, Price/Sales, and Price/Cash Flow, the Value Style Score identifies the most attractive and most discounted stocks.

ADVERTISEMENT

Exelixis (EXEL)

San Francisco, CA-based Exelixis, Inc. is an oncology-focused biotechnology company, which primarily focuses on the discovery, development and commercialization of new drugs for the treatment of difficult-to-treat cancers.

EXEL sits at a Zacks Rank #3 (Hold), holds a Value Style Score of B, and has a VGM Score of A. Compared to the Medical - Biomedical and Genetics industry's P/E of 21.5X, shares of Exelixis are trading at a forward P/E of 23.4X. EXEL also has a PEG Ratio of 0.6, a Price/Cash Flow ratio of 26.9X, and a Price/Sales ratio of 4.4X.

Many value investors pay close attention to a company's earnings as well. For EXEL, three analysts revised their earnings estimate upwards in the last 60 days, and the Zacks Consensus Estimate has increased $0.00 to $0.89 per share for 2022. Per share EXEL boasts an average earnings surprise of 206.9%.

With strong valuation and earnings metrics, a good Zacks Rank, and top-tier Value and VGM Style Scores, investors should strongly think about adding EXEL to their portfolios.


Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
 
Exelixis, Inc. (EXEL) : Free Stock Analysis Report
 
To read this article on Zacks.com click here.
 
Zacks Investment Research